Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2MB
|
|||
| Former ID |
DAP000485
|
|||
| Drug Name |
Oxprenolol
|
|||
| Synonyms |
Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04] | Approved | [1], [2], [3], [4] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H23NO3
|
|||
| Canonical SMILES |
CC(C)NCC(COC1=CC=CC=C1OCC=C)O
|
|||
| InChI |
1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
|
|||
| InChIKey |
CEMAWMOMDPGJMB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 6452-71-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
597348, 5204100, 7980224, 8152843, 10531628, 11467085, 11468205, 11486673, 14750338, 29223720, 46508996, 47217074, 47365481, 47885676, 48110749, 49699389, 50022613, 50195457, 57322363, 81065509, 85220236, 85788907, 96025005, 103176474, 104098253, 104306967, 126428554, 127613395, 134337778, 134988108, 135048217, 135048218, 137111941, 142640337, 160964820, 163228832, 178103829, 179150852, 224791627, 226406507, 241041980, 241128481, 249934544
|
|||
| ChEBI ID |
CHEBI:91704
|
|||
| ADReCS Drug ID | BADD_D01641 | |||
| SuperDrug ATC ID |
C07AA02
|
|||
| SuperDrug CAS ID |
cas=006452717
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Antagonist | [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7255). | |||
| REF 2 | Controlled evaluation of the beta adrenoceptor blocking drug oxprenolol in anxiety. Med J Aust. 1976 Jun 12;1(24):909-12. | |||
| REF 3 | The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. | |||
| REF 4 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018166. | |||
| REF 5 | Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.